ADVENZYMES

What Advanced Enzyme Technologies promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q1 FY27

what the last two calls moved 14 tracked 3 delivered 3 missed 8 open
  • Anti-inflammatory Products EU Approval went quiet said Q4 FY26 Promised: approval during this year (FY27) Q1 FY27: No specific update provided on the EU approval for anti-inflammatory products in the Q1 FY27 call.
  • FY27 Revenue Growth at risk said Q4 FY26 Promised: double-digit Q1 FY27: Q1 revenue grew only 2% YoY (approx. 7.4% adjusted for sales reversal), a soft start against the 'double-digit' target. Management reiterated confidence but the initial performance puts the goal at risk.
  • FY26 Revenue Growth delivered said Q4 FY25 Promised: mid-double-digit number Q4 FY26: FY26 total revenue grew 17% YoY, meeting the original 'mid-double-digit' guidance despite confusing language in Q3.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 14 tracked commitments for Advanced Enzyme Technologies — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens